Pacific Defense Selected for U.S. Army CMFF Program
27.3.2025 16:47:00 EET | Business Wire | Press release
Pacific Defense, the leader in C5ISR Modular Open Suite of Standards (CMOSS) products and integrated mission systems, has been selected for the contract definition phase of the United States Army’s CMOSS Mounted Form Factor (CMFF) Mounted Common Infrastructure (MCI), an Other Transaction Authority (OTA) contract evaluation. This phase aligns contract work scope and deliverables, fostering innovation and successful program execution post contract award. Leading a team of select industry partners that includes Thales Defense & Security Inc., BAE Systems, Palantir, MAXISIQ, Regal Technology Partners, and STC, an Arcfield company, Pacific Defense is ready to deploy a comprehensive capability set to accelerate the U.S. Army's vision for CMFF.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250327094467/en/
Pacific Defense CMOSS Mounted Form Factor (CMFF) revolutionizes communications, command, and control across U.S. Army ground and aviation platforms, enabling maneuver commanders to maintain a decisive advantage over peer and near-peer adversaries.
"The future of innovation for the warfighter and the defense industry is here today," said Travis Slocumb, CEO of Pacific Defense. "This milestone represents the culmination of years of hard work and collaboration with our Army and industry partners to deliver transformative solutions that are ready to meet the evolving needs of the modern battlefield. The foundational CMFF MCI investments across ground and aviation platforms unlocks an operating model that allows for rapid, iterative, and cost-effective insertion of hardware and software, significantly reducing the time to deploy and enhance systems.”
The CMFF program, led by PM Mission Command within Program Executive Office Command, Control, Communications, and Network (PEO C3N) at Aberdeen Proving Ground, is set to revolutionize communications, command, and control across U.S. Army ground and aviation platforms, enabling maneuver commanders to maintain a decisive advantage over peer and near-peer adversaries. Selected under an OTA, Mid-Tier Acquisition (MTA), this program accelerates the delivery of cutting-edge technology to the warfighter.
About Pacific Defense
Pacific Defense is purpose-built to drive the open systems transformation necessary to unlock rapid innovation and the power of commercial technology. Specializing in C5ISR and Electronic Warfare (EW) solutions for mission-critical environments, Pacific Defense leverages Modular Open Systems Architecture (MOSA) standards to deliver innovative, adaptable technology that enables faster response to emerging threats and evolving mission requirements. Learn more at www.pacific-defense.com and on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250327094467/en/
Contacts
Pacific Defense Media Contact
Lea Ramthun - marketing@pacific-defense.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom